



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



MYCi975

Item No. 39622

CAS Registry No.: 2289691-01-4
Formal Name: 4'-chloro-6-[(4-chlorophenyl)methoxy]-3-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-3'-(trifluoromethyl)-[1,1'-biphenyl]-2-ol
Synonym: NUCC-0200975
MF: C₂₅H₁₆Cl₂F₆N₂O₂
FW: 561.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MYCi975 is supplied as a solid. A stock solution may be made by dissolving the MYCi975 in the solvent of choice, which should be purged with an inert gas. MYCi975 is soluble in acetonitrile and DMSO.

Description

MYCi975 is an inhibitor of the protein-protein interaction between Myc and Myc-associated factor X (MAX).¹ It binds to Myc ($K_d = 2.75 \mu\text{M}$) and increases GSK3 β -mediated Myc phosphorylation in a cell-free assay. MYCi975 (5 and 10 μM) decreases the viability of MyC-CaP and LNCaP prostate cancer cells. It induces apoptosis in a panel of 11 breast cancer cell lines when used at a concentration of 10 μM .² *In vivo*, MYCi975 (100 mg/kg) reduces tumor volume in a MyC-CaP mouse xenograft model.

References

1. Han, H., Jain, A.D., Truica, M.I., *et al.* Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. *Cancer Cell* **36(5)**, 483-497 (2019).
2. Tang, M., O'Grady, S., Crown, J., *et al.* MYC as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigations with the novel MYC inhibitor, MYCi975. *Breast Cancer Res. Treat.* **195(2)**, 105-115 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/14/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM